Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
Molecular Cancer Therapeutics
Journal
Overview
Identity
Overview
Publication Venue For
Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1–Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow
. 21:347-358.
2022
Strategies in overcoming homologous recombination proficiency and PARP inhibitor resistance
. 20:1542-1549.
2021
Gene expression signature correlates with outcomes in metastatic renal cell carcinoma patients treated with everolimus alone or with a vascular disrupting agent
. 20:1454-1461.
2021
Neutralization of TGFβ improves tumor immunity and reduces tumor progression in ovarian carcinoma
. 20:602-611.
2021
RANKL-targeted combination therapy with osteoprotegerin variant devoid of trail binding exerts biphasic effects on skeletal remodeling and antitumor immunity
. 19:2585-2597.
2020
Comparison of panitumumab-IRDye800CW and 5-aminolevulinic acid to provide optical contrast in a model of glioblastoma multiforme
. 19:1922-1929.
2020
CHK1/2 inhibitor prexasertib suppresses notch signaling and enhances cytotoxicity of cisplatin and radiation in head and neck squamous cell carcinoma
. 19:1279-1288.
2020
Identification of ALDH1A3 as a viable therapeutic target in breast cancer metastasis-initiating cells
. 19:1134-1147.
2020
B-arrestins regulate stem cell-like phenotype and response to chemotherapy in bladder cancer
. 18:801-811.
2019
Prognostic and biologic relevance of clinically applicable long noncoding RNA profiling in older patients with cytogenetically normal acute myeloid leukemia
. 18:1451-1459.
2019
Retraction: γ-tocotrienol promotes trail-induced apoptosis through reactive oxygen species/extracellular signal-regulated kinase/P53–mediated upregulation of death receptors (Molecular Cancer Therapeutics (2010) 9 (2196–207) DOI: 10.1158/1535-7163.MCT-10-0277)
. 17:2072.
2018
Nuclear factor-kb promotes urothelial tumorigenesis and cancer progression via cooperation with androgen receptor signaling
. 17:1303-1314.
2018
Trastuzumab-resistant HER2
þ
breast cancer cells retain sensitivity to poly (adp-ribose) polymerase (parp) inhibition
. 17:921-930.
2018
Histone methyltransferase ezh2: A therapeutic target for ovarian cancer
. 17:591-602.
2018
JQ1 induces DNA damage and apoptosis, and inhibits tumor growth in a patient-derived xenograft model of cholangiocarcinoma
. 17:107-118.
2018
Combining Chk1/2 inhibition with cetuximab and radiation enhances in vitro and in vivo cytotoxicity in head and neck squamous cell carcinoma
. 16:591-600.
2017
Preclinical evaluation of UAB30 in pediatric renal and hepatic malignancies
. 15:911-921.
2016
SPARC-independent delivery of nab-paclitaxel without depleting tumor stroma in patient-derived pancreatic Cancer xenografts
. 15:680-688.
2016
The TMPRSS2-ERG gene fusion blocks XRCC4-mediated nonhomologous end-joining repair and radiosensitizes prostate cancer cells to PARP inhibition
. 14:1896-1906.
2015
Preclinical evaluation of a novel RXR agonist for the treatment of neuroblastoma
. 14:1559-1569.
2015
Efficacy of carboplatin alone and in combination with ABT888 in intracranial murine models of BRCA-mutated and BRCA-wild-type triple-negative breast cancer
. 14:920-930.
2015
Tumor-suppressor role of notch3 in medullary thyroid carcinoma revealed by genetic and pharmacological induction
. 14:499-512.
2015
Effect of niclosamide on basal-like breast cancers
. 13:800-811.
2014
Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers
. 12:2110-2120.
2013
Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924
. 12:1958-1967.
2013
Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress wnt/β-catenin signaling
. 12:1848-1858.
2013
Resveratrol induces differentiation markers expression in anaplastic thyroid carcinoma via activation of Notch1 signaling and suppresses cell growth
. 12:1276-1287.
2013
Triptolide induces the expression of miR-142-3p: A negative regulator of heat shock protein 70 and pancreatic cancer cell proliferation
. 12:1266-1275.
2013
A novel sulindac derivative inhibits lung adenocarcinoma cell growth through suppression of Akt/mTOR signaling and induction of autophagy
. 12:663-674.
2013
Smoking induces epithelial-to-mesenchymal transition in non-small cell lung cancer through HDAC-mediated downregulation of E-cadherin
. 11:2362-2372.
2012
Therapeutic potential of AZD1480 for the treatment of human glioblastoma
. 10:2384-2393.
2011
3,5-bis(2,4-difluorobenzylidene)-4-piperidone, a novel compound that affects pancreatic cancer growth and angiogenesis
. 10:2146-2156.
2011
Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy
. 9:2536-2544.
2010
Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: Evidence from a xenograft study
. 9:1525-1535.
2010
Identification of a novel Raf-1 pathway activator that inhibits gastrointestinal carcinoid cell growth
. 9:429-437.
2010
γ-Tocotrienol promotes TRAIL-induced apoptosis through reactive oxygen species/extracellular signal-regulated kinase/p53-mediated upregulation of death receptors
. 9:2196-2207.
2010
Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G
. 8:3331-3340.
2009
Efficacy of IGFBP7 for treatment of metastatic melanoma and other cancers in mouse models and human cell lines
. 8:3009-3014.
2009
Experimental cancer therapy using restoration of NAD
+
-linked 15-hydroxyprostaglandin dehydrogenase expression
. 8:3130-3139.
2009
Radiosensitization of solid tumors by Z-VAD, a pan-caspase inhibitor
. 8:1270-1279.
2009
Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-3β
. 8:914-920.
2009
The small organic compound HMN-176 delays satisfaction of the spindle assembly checkpoint by inhibiting centrosome-dependent microtubule nucleation
. 8:592-601.
2009
Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors
. 8:350-356.
2009
CXCR4-gp120-IIIB interactions induce caspase-mediated apoptosis of prostate cancer cells and inhibit tumor growth
. 8:178-184.
2009
Molecular chemotherapy of pancreatic cancer using novel mutant bacterial cytosine deaminase gene
. 7:2845-2854.
2008
Chemoprevention by perillyl alcohol coupled with viral gene therapy reduces pancreatic cancer pathogenesis
. 7:2042-2050.
2008
TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth
. 6:3198-3207.
2007
Enterolactone induces apoptosis in human prostate carcinoma LNCaP cells via a mitochondrial-mediated, caspase-dependent pathway
. 6:2581-2590.
2007
The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion
. 6:2449-2457.
2007
Use of fluorescent labeled anti-epidermal growth factor receptor antibody to image head and neck squamous cell carcinoma xenografts
. 6:1230-1238.
2007
High-resolution single-photon emission computed tomography and X-ray computed tomography imaging of Tc-99m-labeled anti-DR5 antibody in breast tumor xenografts
. 6:866-875.
2007
Inactivation of glycogen synthase kinase-3β, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells
. 6:1151-1158.
2007
Treatment of prostate cancer with Ad5/3Δ24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo
. 6:742-751.
2007
Antiangiogenic activity of 4′-thio-β-D-arabinofuranosylcytosine
. 5:2218-2224.
2006
Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells
. 5:2310-2316.
2006
Silymarin inhibits UV radiation-induced immunosuppression through augmentation of interleukin-12 in mice
. 5:1660-1668.
2006
Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapy
. 5:1577-1584.
2006
Interleukin-12-deficient mice are at greater risk of UV radiation-induced skin tumors and malignant transformation of papillomas to carcinomas
. 5:825-832.
2006
ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells
. 4:910-917.
2005
Characterization of inhibitors of specific carboxylesterases: Development of carboxylesterase inhibitors for translational application
. 3:903-909.
2004
Telomerase inhibition by retinoids precedes cytodifferentiation of leukemia cells and may contribute to terminal differentiation
. 3:1003-1009.
2004
SB-431542, a small molecule transforming growth factor-β-receptor antagonist, inhibits human glioma cell line proliferation and motility
. 3:737-745.
2004
The novel estrogen 17α-20Z-21-[(4-amino)phenyl]-19-norpregna-1,3,5(10),20-tetraene-3, 17β-diol induces apoptosis in prostate cancer cell lines at nanomolar concentrations in vitro
. 3:587-595.
2004
Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter-driven E1A, E4, or both in submerged cells and organotypic cultures
. 3:437-449.
2004
Homologous recombination is a highly conserved determinant of the synergistic cytotoxicity between cisplatin and DNA topoisomerase I poisons
. 3:393-402.
2004
Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies
. 2:1171-1181.
2003
Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: Implications for a dual modality treatment using capecitabine and irradiation
. 1:1139-1145.
2002
Transforming growth factor β mimetics: Discovery of 7-[4-(4-cyanophenyl) phenoxy]-heptanohydroxamic acid, a biaryl hydroxamate inhibitor of histone deacetylase
. 1:759-768.
2002
p53 mediates DNA damaging drug-induced apoptosis through a caspase-9-dependent pathway in SH-SY5Y neuroblastoma cells
. 1:679-686.
2002
A model system for the design of armed replicating adenoviruses using p53 as a candidate transgene
. 1:321-328.
2002
Identity
International Standard Serial Number (issn)
1535-7163
Electronic International Standard Serial Number (eissn)
1538-8514